Peptide Research Protocols: Applications and Guidelines

Understanding Peptide Protocols

Peptide research protocols represent systematic approaches to investigating specific biological outcomes using peptide compounds. This comprehensive guide covers 20 of the most commonly researched applications, detailing which peptides are being studied, typical research dosing, administration methods, and critical regulatory considerations.

Each protocol includes:

• Primary peptides: Compounds most commonly associated with the application
• Dosing guidelines: Typical research doses from clinical trials and studies
• Administration: Delivery method, frequency, and timing
• Duration: Typical research protocol length
• Regulatory status: FDA approval status, WADA prohibitions, safety concerns
• Evidence quality: Strength of research supporting the application

Quick Navigation

Regulatory Considerations

FDA Approval Status

It is critical to understand the regulatory status of peptides before considering any research application:

FDA-Approved Peptides (for specific indications):

• Semaglutide (Ozempic, Wegovy): Type 2 diabetes, chronic weight management
• Tirzepatide (Mounjaro, Zepbound): Type 2 diabetes, chronic weight management
• Liraglutide (Victoza, Saxenda): Type 2 diabetes, chronic weight management
• Tesamorelin (Egrifta): HIV-associated lipodystrophy ONLY (not general weight loss)
• PT-141/Bremelanotide (Vyleesi): Female hypoactive sexual desire disorder (HSDD)
• Desmopressin: Diabetes insipidus, bedwetting
• Oxytocin: Labor induction

Unapproved Peptides (No FDA approval for any indication):

• BPC-157, TB-500, CJC-1295, Ipamorelin, GHRP-6, Sermorelin, Hexarelin
• Melanotan I/II, GHK-Cu, Selank, Semax, DSIP
• Kisspeptin, MOTS-c, Humanin, Epitalon, Follistatin-344, AOD-9604
• Thymosin Alpha-1 (approved in some countries, not FDA-approved in US)

FDA Warnings and Safety Concerns

The FDA has issued specific warnings about several peptides:

Compounding Safety Concerns:

• GLP-1 agonists: FDA warns about unapproved salt forms and quality issues with compounded versions
• Ipamorelin: FDA reviewed for compounding with safety concerns identified
• Kisspeptin: FDA flags compounding risks
• MOTS-c: Listed as posing compounding safety concerns
• Thymosin Alpha-1: FDA highlights compounding safety concerns and lack of adequate safety data

Illegal/Unsafe Products:

• Melanotan I/II: Repeatedly flagged as illegal/unsafe by FDA, TGA, and other health agencies
• BPC-157: DoD's OPSS and USADA highlight risks; not approved as drug or supplement
• TB-500: Similar warnings from OPSS and USADA

WADA Prohibited Substances

Athletes subject to drug testing should be aware that many peptides are prohibited by the World Anti-Doping Agency (WADA):

Prohibited at All Times:

• S2. Peptide Hormones, Growth Factors: GH, IGF-1, GHRH analogs (CJC-1295, Tesamorelin, Sermorelin)
• GH Secretagogues: Ipamorelin, GHRP-6, Hexarelin
• S0. Non-Approved Substances: AOD-9604, Follistatin-344, TB-500, BPC-157
• Myostatin Inhibitors: Follistatin and related agents

Consequences:

• Positive test results in sanctions (2-4 year bans)
• Applies to all competitive athletes under WADA code
• Includes NCAA, professional sports, Olympic sports

Evidence Quality Levels

Understanding the strength of evidence supporting each protocol is essential:

Level 1 (Strong Evidence):

• Multiple large randomized controlled trials (RCTs)
• FDA approval for indication
• Consistent results across studies
• Examples: Semaglutide for weight loss, Tesamorelin for HIV lipodystrophy

Level 2 (Moderate Evidence):

• Some RCTs or multiple observational studies
• Mechanistic plausibility
• Results generally consistent but limited data
• Examples: PT-141 for erectile function (off-label), Kisspeptin for fertility

Level 3 (Limited Evidence):

• Small studies, case reports, animal data
• Mechanistic rationale but limited human data
• Results inconsistent or preliminary
• Examples: Semax/Selank for cognition, DSIP for sleep

Level 4 (Minimal/No Evidence):

• Primarily anecdotal reports
• No controlled human studies
• Theoretical mechanisms only
• Examples: BPC-157 for gut healing, MOTS-c for longevity

Safety Considerations Across All Protocols

General Safety Principles

• Source quality: Peptide purity and identity vary widely; compounded products may contain impurities
• Injection risks: Infection, injection site reactions, improper technique
• Immunogenicity: Peptides can trigger antibody formation, reducing efficacy or causing reactions
• Long-term effects: Unknown for most unapproved peptides
• Drug interactions: May interact with medications, especially diabetes drugs
• Contraindications: Many peptides contraindicated in pregnancy, cancer history, certain medical conditions

Red Flags Requiring Medical Evaluation

• Severe allergic reactions (anaphylaxis)
• Persistent injection site reactions
• Unexpected symptoms or side effects
• Worsening of pre-existing conditions
• Signs of infection

How to Use This Resource

1. Identify your research interest: Select from the 20 protocol categories
2. Review the detailed protocol: Each has its own comprehensive page
3. Understand regulatory status: Note FDA approval status and WADA prohibitions
4. Assess evidence quality: Consider strength of research supporting the application
5. Review safety information: Understand risks and contraindications
6. Consult peptide-specific pages: Deep dive into individual peptides for complete information

Disclaimer and Responsible Use

This resource is provided for educational and research purposes only. The information presented here:

• Does NOT constitute medical advice
• Should NOT be used to self-prescribe or self-administer peptides
• Describes research protocols, not approved medical treatments
• Includes many unapproved, illegal, or unsafe compounds
• Is intended for researchers, healthcare professionals, and educated consumers

Many peptides discussed here are:

• Not approved by the FDA for any indication
• Prohibited in competitive sports
• Associated with significant safety concerns
• Illegal to market or sell for human consumption
• Subject to quality control issues when compounded

Always consult qualified healthcare professionals before considering any peptide-based intervention.